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Effectiveness results
A significantly higher loading dose was administered to ATM patients compared to the non-guided TDM group (202 versus 136 mg; p<0.001).
Maintenance dosages in ATM patients were significantly higher (175 versus 127 mg; p<0.001). This resulted in significantly higher peak concentrations (10.6 versus 7.6 mg/L; p<0.001).
The dosage interval was significantly longer in the ATM group (19 versus 14 hours; p<0.001) and gave better target trough concentrations (0.7 versus 1.4 mg/L; p<0.001).
The proportion of dose adjustments was 48.6% with ATM and 80.4% with non-guided TDM, (p=0.016).
There was a trend towards lower mortality in the ATM group (9 of 105 versus 18 of 127 patients died; p=0.26) that was significant for ATM patients admitted to the hospital with an infection (1 of 48 versus 9 of 62 patients died; p=0.023).
There was significantly less nephrotoxicity in the ATM patients compared to non-guided TDM patients (2.9 versus 13.4%; p<0.01).
The number of days with signs of infection was 4.8 with ATM and 3.4 with non-guided TDM (p=0.003).
The number of febrile days was 2.8 with ATM and 2.3 with non-guided TDM (p=0.024).
Clinical conclusions
The authors argued that a goal-oriented, model-based aminoglycoside dosing strategy contributes to achieving desired target serum concentrations in patients with a suspected or proven Gram-negative infection and treated with an aminoglycoside.
Measure of benefits used in the economic analysis
The outcome measures used in the economic analysis were survival and number of days alive after discharge from the hospital.
Direct costs
Direct costs were not discounted due to the short time horizon of the study (less than one year). Quantities and costs were reported separately. Direct costs related to costs of hospitalisation and major diagnostic and therapeutic interventions. The quantity/cost boundary adopted was that of the hospital. Diagnostic and therapeutic interventions were valued using the Dutch reimbursement system. The price year was not reported. The length of hospital stay was 20 days with ATM and 26.3 days with non-guided TDM, (p=0.045). The number of days of aminoglycoside therapy was 5.9 with ATM and 8.0 with non-guided TDM, (p<0.001).
